<DOC>
	<DOCNO>NCT01433328</DOCNO>
	<brief_summary>Treprostinil subcutaneous ( skin ) infusion good medication treat pulmonary arterial hypertension infusion site pain may severe patient . The investigator plan treat patient receive treprostinil subcutaneous infusion lidocaine ( local anesthestic ) treat pain .</brief_summary>
	<brief_title>Lidocaine Subcutaneous Infusion Control Treprostinil Related Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>PAH Treprostinil treatment least 3 month Severe infusion site pain Pregnancy/breastfeeding Decompensated heart failure Chronic liver disease Abnormal electrolytes Heart block ( 2/3 degree ) , sinoatrial block , idioventricular rhythm Systolic systemic BP &lt; 90mmHg Bradycardia HR &lt; 55 Adverse reaction lidocaine amide local anesthestic Interacting medication ( antiarrhythmic , CYP1A2 inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Remodulin</keyword>
	<keyword>Treprostinil</keyword>
</DOC>